Back to Search Start Over

Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients With Use of Single-Pill Combinations: Results From the START-Study.

Authors :
Schmieder, Roland E.
Wassmann, Sven
Predel, Hans-Georg
Weisser, Burkhard
Blettenberg, Jörg
Gillessen, Anton
Randerath, Olaf
Mevius, Antje
Wilke, Thomas
Böhm, Michael
Source :
Hypertension (0194911X); May2023, Vol. 80 Issue 5, p1127-1135, 9p
Publication Year :
2023

Abstract

Background: Single-pill combination improves adherence and persistence to medication in hypertension. It remains unclear whether this also reduces cardiovascular outcomes and all-cause mortality. We analyzed whether single-pill combinations are superior to identical multiple pills on persistence to medication, cardiovascular outcomes, and all-cause mortality. Methods: This was a retrospective claims data (German AOK PLUS) analysis. Data from hypertensive patients ≥18 years treated with renin-angiotensin system combinations given as single pill or identical multipills covering the years 2012 to 2018 were analyzed and followed up to at least 1 year. After 1:1 propensity score matching, persistence to medication, cardiovascular events, and all-cause mortality were compared using non-parametric tests. Results were reported as incidence rate ratios and hazard ratios. Results: After propensity score matching data from 57 998 patients were analyzed: 10 801 patients received valsartan/amlodipine, 1026 candesartan/amlodipine, 15 349 ramipril/amlodipine, and 1823 amlodipine/valsartan/hydrochlorothiazide as single pill or identical multipill. No relevant differences in patient characteristics were observed within the 4 groups. In all groups, a significant lower all-cause mortality, a significant a higher persistence to medication, a significant lower event rate in 15 out of 20 comparisons, and a tendency in the remaining 5 comparisons was observed under single pills compared with multipill combinations. Conclusions: Antihypertensive combination therapy reduces all-cause mortality and cardiovascular when provided as single pill compared to identical drugs as multipills. This strongly supports the European Society of Cardiology/European Society of Hypertension and International Society of Hypertension guidelines recommending the use of a single-pill combination and thus should be more rigorously implemented into daily clinical practice. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
0194911X
Volume :
80
Issue :
5
Database :
Supplemental Index
Journal :
Hypertension (0194911X)
Publication Type :
Academic Journal
Accession number :
163109657
Full Text :
https://doi.org/10.1161/HYPERTENSIONAHA.122.20810